WOLVERINE
BPC-157 10mg · TB-500 10mg · Lyophilised Recovery Stack
Recovery at the
cellular frontier.
WOLVERINE is designed for researchers investigating the biology of accelerated structural repair. BPC-157 — a partial sequence of body protection compound originally identified in human gastric mucosa — has accumulated one of the most extensive preclinical dossiers of any research peptide. Published studies in tendon, ligament, bone, muscle, and intestinal tissue models have consistently associated BPC-157 with accelerated healing timelines, reduced inflammatory cascades, and the upregulation of growth factor receptors critical to angiogenesis and cellular migration. Its mechanism appears to involve modulation of FAK-paxillin signalling and the nitric oxide pathway — effects that translate to improved vascularisation at injury sites.
TB-500, a synthetic analogue of Thymosin Beta-4, operates through a complementary but distinct pathway: its binding to G-actin sequesters monomeric actin, prevents premature polymerisation, and promotes the upregulation of LAMA5, a laminin subunit involved in basement membrane integrity and directional cell migration. In musculoskeletal research models, the BPC-157 / TB-500 combination has been studied for synergistic effects on collagen fibre organisation, tenocyte proliferation, and vascular network restoration — making WOLVERINE the reference stack for serious tissue repair investigation.
BPC-157 · 10mg
Cytoprotective pentadecapeptide. FAK-paxillin and NO-pathway modulator studied extensively in tendon, bone, muscle, and gut healing models across hundreds of peer-reviewed publications.
TB-500 · 10mg
G-actin sequestrant and LAMA5 upregulator. Studied for directional cell migration, tenocyte proliferation, and vascular network restoration at wound sites in multiple tissue types.
Synergistic Dual-Pathway Action
Complementary mechanisms converge on vascular remodelling, ECM organisation, and inflammatory resolution — positioning WOLVERINE as the gold-standard recovery research stack.
